Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID®, Presented at ASCO Plenary Session2009-05-31 10:30 ET - News Release
Also News Release (U-ABPI) ACCENTIA BIOPHARMACEUTICALS INC
First lymphoma vaccine to demonstrate disease-free survival benefit
Compassionate-use program to soon launch in Europe
TAMPA, Fla. -- (Business Wire)
Biovest International, Inc. (Other OTC: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ) today announced that an eight year pivotal, randomized, multi-center, double-blind, controlled Phase III clinical study has shown that BiovaxID® (personalized therapeutic anti-cancer vaccine) significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma. The study, which is being featured at today’s American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine – an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first ever vaccine targeting lymphoma to demonstrate such a disease-free survival benefit.
Aucun commentaire:
Enregistrer un commentaire